Frances Mae West

Frances Mae West

Auto-generated profile, based on publicly available information

Frances Mae West

Division of Pulmonary and Critical Care Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA; Department of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
JGJay Giri
Jay Giri
FMFelix Mahfoud
Felix Mahfoud
BGBernhard Gebauer
Bernhard Gebauer
AAAsger Andersen
Asger Andersen
OFOren Friedman
Oren Friedman
FWFrances M. West
Frances M. West
Anticoagulation (AC) is the guideline-recommended treatment for intermediate-risk pulmonary embolism (PE); however, it remains unclear whether mechanical thrombectomy provides benefit over AC alone. The PEERLESS II study aims to evaluate outcomes in intermediate-risk PE patients randomized to treatment with large-bore mechanical thrombectomy and AC vs AC alone. PEERLESS II is an international randomized controlled trial enrolling up to 1200 patients with intermediate-risk PE and additional clinical risk factors from up to 100 sites. Treatment is randomized 1:1 to large-bore mechanical thrombectomy with the FlowTriever System (Inari Medical) and AC or AC alone. Outcomes will be evaluated for up to 3 months, with safety events independently adjudicated. The primary end point is a hierarchical composite win ratio of (1) all-cause mortality by 30 days, (2) clinical deterioration (earlier of discharge or 30 days), (3) all-cause hospital readmission by 30 days, (4) bailout therapy (earlier of discharge or 30 days), and (5) Modified Medical Research Council (mMRC) dyspnea score of ≥1 at the 48-hour visit. Secondary end points include all-cause and PE-related mortality (30-day and 90-day), all-cause and PE-related readmission (30-day and 90-day), major bleeding (30-day and 90-day), clinical deterioration (earlier of discharge or 30 days), bailout (earlier of discharge or 30 days), right ventricle-to-left ventricle diameter ratio (48-hour visit), mMRC dyspnea score (48-hour, 1-month, and 3-month visits), quality of life using Pulmonary Embolism Quality of Life and EuroQol-5 Dimensions-5 Levels (1-month and 3-month visits), 6-minute walk distance (1-month visit), and post-PE impairment diagnosis (3-month visit). PEERLESS II will inform the understanding of mechanical thrombectomy treatment for intermediate-risk PE and provide evidence for consideration in future treatment guidelines.

9 May 2024 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
JMJohn M. Moriarty
John M. Moriarty
SDSuhail Y. Dohad
Suhail Y. Dohad
BSBrian J. Schiro
Brian J. Schiro
HTHouman Tamaddon
Houman Tamaddon
RHRobert E. Heithaus
Robert E. Heithaus
IWIdo Weinberg
Ido Weinberg
To report 90-day results from the first interim analysis of the STRIKE-PE study, which is evaluating safety, effectiveness, and functional and quality of life (QoL) outcomes of Computer Assisted Vacuum Thrombectomy (CAVT) with the Indigo Aspiration System for the treatment of acute pulmonary embolism (PE). STRIKE-PE is a prospective, international, multicenter study that will enroll 600 adult patients with acute PE of ≤14 days and a right ventricle/left ventricle (RV/LV) ratio of ≥0.9 who receive first-line endovascular treatment with CAVT. Primary endpoints are change in RV/LV ratio and incidence of composite major adverse events (MAEs) within 48 hours. Secondary endpoints include functional and QoL assessments. The first 150 consecutive patients were treated with Lightning 12 CAVT. Mean age was 61.3 years, 54.7% were men, 94.7% presented with intermediate-risk PE, and 5.3% presented with high-risk PE. Median thrombectomy and procedure times were 33.5 minutes and 70 minutes, respectively, resulting in a mean reduction in systolic pulmonary artery pressure of 16.3% (P < .001). Mean RV/LV ratio decreased from 1.39 before thrombectomy to 1.01 at 48 hours, a 25.7% reduction (P < .001). Four patients (2.7%) experienced a composite MAE within 48 hours. At 90-day follow-up, patients exhibited statistically significant improvements in the Borg dyspnea scale and QoL measures, and the NYHA class distribution returned to that reported before the index PE. These interim results demonstrate a rapid reduction in RV/LV ratio, achieved with a fast thrombectomy time while maintaining safety. This is accompanied by improvements in 90-day functional and QoL outcomes.

22 April 2024 in POCUS Journal
Verified
Journal Article
Open access
PDF file
BOBrandon Oto
Brandon Oto
RBRobert Baeten
Robert Baeten
LCLeon Chen
Leon Chen
PDPuja Dalal
Puja Dalal
RDRia Dancel
Ria Dancel
ASAarti Sarwal
Aarti Sarwal
Despite the growing use of point of care ultrasound (POCUS) in contemporary medical practice and the existence of clinical guidelines addressing its specific applications, there remains a lack of standardization and agreement on optimal practices for several areas of POCUS use. The Society of Point of Care Ultrasound (SPOCUS) formed a working group in 2022 to establish a set of recommended best practices for POCUS, applicable to clinicians regardless of their training, specialty, resource setting, or scope of practice. Using a three-round modified Delphi process, a multi-disciplinary panel of 22 POCUS experts based in the United States reached consensus on 57 statements in domains including: (1) The definition and clinical role of POCUS; (2) Training pathways; (3) Credentialing; (4) Cleaning and maintenance of POCUS devices; (5) Consent and education; (6) Security, storage, and sharing of POCUS studies; (7) Uploading, archiving, and reviewing POCUS studies; and (8) Documenting POCUS studies. The consensus statements are provided here. While not intended to establish a standard of care or supersede more targeted guidelines, this document may serve as a useful baseline to guide clinicians, leaders, and systems considering initiation or enhancement of POCUS programs.

2 September 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
JMJohn M. Moriarty
John M. Moriarty
BSBrian J. Schiro
Brian J. Schiro
SDSuhail Dohad
Suhail Dohad
HTHouman Tamaddon
Houman Tamaddon
HDHugh C. Davis
Hugh C. Davis
IWIdo Weinberg
Ido Weinberg
Background: Pulmonary embolism (PE) can be a life‐threatening condition. Endovascular treatment is emerging as a promising treatment to restore hemodynamic stability and reverse right ventricular (RV) dysfunction in PE; however, more studies are needed to elucidate the effects on the right ventricle after endovascular treatment. This analysis reports the effects of computer assisted vacuum thrombectomy on RV function. Methods: Eligible patients for the single‐arm, prospective, international, multicenter STRIKE‐PE (A Prospective, Multicenter Study of the Indigo Aspiration System Seeking to Evaluate the Long‐Term Safety and Outcomes of Treating Pulmonary Embolism) cohort study are adults with acute PE with symptoms for ≤14 days and an RV/left ventricular ratio of ≥0.9 who are treated with computer assisted vacuum thrombectomy. Reported here are periprocedural and RV outcomes of the initial 300 patients of STRIKE‐PE, to provide insights into effects on RV function after computer assisted vacuum thrombectomy. Results: Patients were classified with high‐risk (5.7%), intermediate‐high‐risk (84.7%), or intermediate‐low‐risk (9.7%) PE. Median thrombectomy time was 30 minutes. Mean on‐table systolic pulmonary artery pressure decreased from 51.7 mm Hg to 41.3 mm Hg, a 19.1% reduction ( P <0.001). The change in mean RV/left ventricular ratio from baseline to 48 hours postprocedure (primary effectiveness end point) was a decrease from 1.40 to 0.99, a 26.8% reduction ( P <0.001). Clinical parameters and echocardiographic measures of right heart strain improved from baseline to 48 hours postprocedure ( P <0.001). The rate of composite major adverse events within 48 hours postprocedure (primary safety end point) was 2.0%. Median Borg dyspnea scale at rest decreased from 4.0 at baseline to 0.5 at discharge ( P <0.001). Conclusions: This interim analysis demonstrates that computer assisted vacuum thrombectomy safely and expeditiously improves hemodynamic status, RV function, and perceived dyspnea. Registration: URL: https://clinicaltrials.gov ; Unique Identifier: NCT04798261.

1 September 2017 in Clinical Pulmonary Medicine
Verified
Journal Article
Closed access
DKDina M. Khateeb
Dina M. Khateeb
FWFrances Mae West
Frances Mae West
Advanced lung disease (ALD) is comprised of nonmalignant, life-limiting respiratory diseases such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, and pulmonary arterial hypertension, sharing common symptoms and reduced quality of life (QOL) in their advanced stages. As the US’ population is aging and disease-specific therapies are improving, it is expected that more patients will be diagnosed with ALD and live longer, increasing disability, morbidity, and medical costs because of health care utilization at the end-of-life (EOL). Palliative care provides interdisciplinary care to patients with life-limiting disease throughout the continuum of their illness as a complement to disease-modifying and curative therapies with the purpose of improving QOL. Important components of palliative care include symptom management, advance care planning, and EOL care. The integration of palliative care in disease management has been shown to decrease symptom burden, improve QOL, and reduce medical costs at the EOL, highlighting a significant need in the ALD population. However, when comparing patients with lung cancer to those with ALD, there is a clear disparity in the use of palliative services in ALD patients. Some of the barriers to providing palliative services in ALD are ambiguous disease trajectories, and poor communication between physicians and their patients. All health care providers caring for patients with ALD, especially pulmonologists, should be confident integrating early palliative care measures in this patient population. This article aims to discuss the major components and barriers involved in the palliative management and EOL care in ALD.

19 March 2026 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
HLHana Lim
Hana Lim
MBMichael Bender
Michael Bender
HCHuigen Chen
Huigen Chen
FWFrances M. West
Frances M. West
JLJulio Lanfranco
Julio Lanfranco
KHKatherine A. Hajjar
Katherine A. Hajjar
• Sepsis-triggered proteolysis of A2 reduces cell surface fibrinolytic activity. • A2 proteolysis is associated with microvasculopathic organ dysfunction in humans.